Clinical review: New technologies for prevention of intravascular catheter-related infections

Critical Care

Volumn 8, Issue 3, 2004, Pages 157-162

  Cicalini, Stefania ^a   Palmieri, Fabrizio ^a   Petrosillo, Nicola ^a  

^a IRCCS   (Italy)

Author keywords

Catheter related bloodstream infections; Central venous catheters; New technologies; Prevention

Indexed keywords

ALCOHOL; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; CHLORHEXIDINE; CIPROFLOXACIN; EDETIC ACID; HEPARIN; IODINE DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; MINOCYCLINE; POLYURETHAN; POVIDONE IODINE; RIFAMPICIN; SILVER; SULFADIAZINE SILVER; VANCOMYCIN; WARFARIN;

ANAPHYLAXIS; BANDAGES AND DRESSINGS; BLOOD CLOT LYSIS; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CHRONIC DISEASE; CHRONIC PATIENT; CLINICAL TRIAL; CONTACT DERMATITIS; CRITICAL ILLNESS; DRUG COST; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTRAVASCULAR CATHETER; IONTOPHORESIS; MEDICAL TECHNOLOGY; MORBIDITY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; THROMBOSIS;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTIBIOTIC PROPHYLAXIS; BANDAGES; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; CROSS INFECTION; DRUG DELIVERY SYSTEMS; EQUIPMENT CONTAMINATION; HUMANS; INFECTION CONTROL;

EID: 2942564555     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc2380     Document Type: Review

References (55)

1. Centers for Disease Control and Prevention: Guidelines for the prevention of intravascular catheter-related infections. MMWR Recomm Rep 2002, 51(RR-10):1-29.
2. Mermel LA: New technologies to prevent intravascular catheter-related bloodstream infections. Emerg Infect Dis 2001, 7:197-199.
3. Richet H, Hubert B, Nitemberg G, Andremont A, Buu-Hoi A, Ourbak P, Galicier C, Veron M, Boisivon A, Bouvier AM: Prospective multicenter study of vascular-catheter-related complications and risk factors for positive central-catheter cultures in intensive care unit patients. J Clin Microbiol 1990, 28:2520-2525.
4. Collignon PJ: Intravascular catheter associated sepsis: a common problem. The Australian Study on Intravascular Catheter Associated Sepsis. Med J Aust 1994, 161:374-378.
5. Garland JS, Alex CP, Mueller CD, Otten D, Shivpuri C, Harris MC, Naples M, Pellegrini J, Buck RK, McAuliffe TL, Goldmann DA, Maki DG: A randomised trial comparing povidone-iodine to a chlorhexidine gluconate impregnated dressing for prevention of central venous catheter infections in neonates. Pediatrics 2001, 107:1431-1437.
6. Bonawitz SC, Hammell EJ, Kirkpatrick JR: Prevention of central venous catheter sepsis: a prospective randomized trial. Am Surg 1991, 57:618-623.
7. Maki DG, Cobb L, Garman JK, Chapiro JM, Ringer M, Helgerson RB: An attachable silver-impregnated cuff for prevention of infection with central venous catheters: a prospective randomized multicenter trial. Am J Med 1988, 85:307-314.
8. Flowers RHD, Schenzer KJ, Kopel RF, Fish MJ, Tucker SI, Farr BM: Efficacy of an attachable subcutaneous cuff for the prevention of intravascular catheter-related infection: a randomized, controlled trial. JAMA 1989, 261:878-883.
9. Smith HO, DeVictoria CL, Garfinkel D, Anderson P, Goldberg GL, Soeiro R, Elia G, Runowicz CD: A prospective randomized comparison of an attached silver-impregnated cuff to prevent central venous catheter-associated infection. Gynecol Oncol 1995, 58:92-100.
10. Dahlberg PJ, Agger WA, Singer JR, Yutuc WR, Newcomer KL, Schaper A, Rooney BL: Subclavian haemodialysis catheter infections: a prospective randomized trial of an attachable silver impregnated cuff for prevention of catheter-related infections. Infect Control Hosp Epidemiol 1995, 16:506-511.
11. Groeger JS, Lucas AB, Coit D, LaQuaglia M, Brown AE, Turnbull A, Exelby P: A prospective, randomized evaluation of the effect of silver impregnated subcutaneous cuffs for preventing tunnelled chronic venous access catheter infections in cancer patients. Ann Surg 1993, 218:206-210.
12. Greenfild JI, Sampath L, Popiskis SJ, Brunnert SR, Stylianos S, Modak S: Decreased bacterial adherence and biofilm formation on chlorexidine and silver sulfadiazine impregnated central venous catheters implanted in swine. Crit Care Med 1995, 23:894-900.
13. Kamal GD, Pfaller MA, Rempe LE, Jebson PJ: Reduced intravascular catheter infection by antibiotic bolding. JAMA 1991, 265: 2364-2368.
14. Maki DG, Stolz SM, Wheeler S, Mermel LA: Prevention of central venous catheter-related infection by use of an antiseptic impregnated catheter. A randomized, controlled trial. Ann Intern Med 1997, 127:257-266.
15. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, Wall M, Harris R, Jones J, Buzaid A, Robertson C, Shenaq S, Curling P, Burke T, Ericsson C: Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infection: a randomized, double-bind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 1997, 127:267-274.
16. Bach A, Bohrer H, Motsh J, Martin E, Geiss HK, Sonntag HG: Prevention of bacterial colonization of intravenous catheters by antiseptic impregnation of polyurethane polymers. J Antimicrobial Chemother 1994, 33:969-978.
17. Veenstra DL, Saint S, Saha S, Lumeley T, Sullivan SD: Efficacy of antiseptic-impregnated central venous catheters in preventing catheter related bloodstream infection: a meta-analysis. JAMA 1999, 281:261-267.
18. Bach A, Schmidt H, Bottiger B, Schreiber B, Bohrer H, Motsch J, Martin E, Sonntag HG: Retention of antibacterial activity and bacterial colonization of antiseptic-bonded central venous catheters. J Antimicrob Chemoter 1996, 37:315-322.
19. Logghe C, Van Ossel C, D'Hoore W, Ezzedine H, Wauters G, Haxhe JJ: Evaluation of chlorexidine and silver sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemia patients: a randomized controlled trial. J Hosp Infect 1997, 37:145-156.
20. Raad I, Darouiche R, Hachem R, Mansouri M, Bodey GP: The broad-spectrum activity and efficacy of catheter coated with minocycline and rifampin. J Infect Dis 1996, 173:418-424.
21. Bassetti S, Hu J, D'Agostino RB Jr, Sherertz RJ: Prolonged antimicrobial activity of a catheter containing chlorhexidine-silver sulfadiazine extends protection against catheter infections in vivo. Antimicrob Agents Chemoter 2001, 45: 1535-1538.
22. Oda T, Hamasaki J, Kanda N, Mikami K: Anaphylactic shock induced by an antiseptic-coated central venous catheter. Anesthesiology 1997, 87:1242-1244.
23. Stephens R, Mythen M, Kallis P, Davies DW, Egner W, Rickards A: Two episodes of life-threatening anaphylaxis in the same patient to a chlorhexidine-sulphadiazine-coated central venous catheter. Br J Anaesth 2001, 87:306-308.
24. Crnich CJ, Maki DG: The promise of novel technology for the prevention of intravascular device-related bloodstream infection. I. Pathogenesis and short-term devices. Clin Infect Dis 2002, 34:1232-1242.
25. Darouiche RO, Raad II, Heard SO, Thornby JI, Wenker OC, Gabrielli A, Berg J, Khardori N, Hanna H, Hachem R, Harris RL, Mayhall G: A comparison of two antimicrobial impregnated central venous catheters. N Engl J Med 1999, 340:1-8.
26. Raad II, Darouiche RO, Hachem R, Abi-Said D, Safar H, Darnule T, Mansouri M, Morck D: Antimicrobial durability and rare ultrastructural colonization of indwelling central catheters coated with minocycline and rifampin. Crit Care Med 1998, 26:219-224.
27. Marciante KD, Veenstra DL, Lipsky BA, Saint S: Which antimicrobial impregnated catheter should we use? Modelling the costs and outcomes of antimicrobial catheter use. Am J Infect Control 2003, 31:1-8.
28. Tambe SM, Sampath L, Modak SM: In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices. J Antimicrob Chemother 2001, 47:589-598.
29. Ranucci M, Isgro G, Giomarelli PP, Pavesi M, Luzzani A, Cattabriga I, Carli M, Giomi P, Compostella A, Digito A, Mangani V, Silvestri V, Mondelli E;Catheter Related Infection Trial (CRIT) Group: Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Crit Care Med 2003, 3:52-59.
30. Liu WK, Tebbs SE, Byrne PO, Elliott TS: The effects of electric current on bacteria colonizing intravenous catheters. J Infect 1993, 27:261-269.
31. Raad I, Hachem R, Zermeno A, Dumo M, Bodey GP: In vitro antimicrobial efficacy of silver iontophoretic catheters. Biomaterials 1996, 17:1055-1059.
32. Segura M, Alvarez-Lerma F, Tellado JM, Jimenez-Ferreres J, Oms L, Rello J, Baro T, Sanchez R, Morera A, Mariscal D, Marrugat J, Sitges-Serra A: A clinical trial on the prevention of catheter-related sepsis using a new hub model. Ann Surg 1996, 223: 363-369.
33. Luna J, Masdeu G, Perez M, Claramonte R, Forcadell I, Barrachina F, Panisello M: Clinical trial evaluating a new hub device designate to prevent catheter-related sepsis. Eur J Clin Microbiol Infect Dis 2000, 19:655-662.
34. Halpin DP, O'Byrne P, Mc Entee G, Hennessy TP, Stephens RB: Effects of a Betadine connection shield on central venous catheters sepsis. Nutrition 1991, 7:23-34.
35. Mendelson MH, Short LJ, Schechter CB, Meyers BR, Rodriguez M, Cohen S, Lozada J, DeCambre M, Hirschman SZ: Study of needleless intermittent intravenous access system for peripheral infusions: analysis of staff patient, and institutional outcomes. Infect Control Hosp Epidemiol 1998, 19:401-406.
36. Danzig LE, Short LJ, Collins K, Mahoney M, Sepe S, Bland L, Jarvis WR: Bloodstream infections associated with a needleless intravenous infusion system in patients receiving home infusion therapy. JAMA 1995, 273:1862-1864.
37. Cookson ST, Ihrig M, O'Mara EM, Denny M, Volk H, Banerjee SN, Hartstein AI, Jarvis WR: Increased bloodstream infection rates in surgical patients associated with variation from recommended use and care following implementation of a needleless device. Infect Control Hosp Epidemiol 1998, 19:28-31.
38. Kellerman S, Shay DK, Howard J, Goes C, Feusner J, Rosenberg J, Vugia DJ, Jarvis WR: Bloodstream infections in home infusion patients: the influence of race and needleless intravescular devices. J Pediatr 1996, 129:711-717.
39. Do AN, Ray BJ, Banerjee SN, Illian AF, Barnett BJ, Pham MH, Hendricks KA, Jarvis WR: Bloodstream infection associated with needleless devices use and the importance of infection control practices in the home health care setting. J Infect Dis 1999, 179:442-448.
40. Seymour VM, Dhallu TS, Moss HA, Tebbs SE, Elliot TS: A prospective clinical study to investigate the microbial contamination of a needleless connector. J Hosp Infect 2000, 45:165-168.
41. Rackoff WR, Weiman M, Jakobowski D, Hirschl R, Stallings V, Bilodeau J, Danz P, Bell L, Lange B: A randomized, controlled trial of the efficacy of a heparin and vancomycin solution in preventing central venous catheter infection in children. J Pediatr 1995, 127:147-151.
42. Shwartz C, Henrickson KJ, Roghmann K, Powell K. Prevention of bacteremia attributed to luminal colonization of tunnelled central venous catheter with vancomycin susceptible organisms. J Clin Oncol 1990, 8:591-597.
43. Raad II, Hanna HA: Intravascular catheter-related infections. New horizons and recent advances. Arch Intern Med 2002, 162:871-878.
44. Henrickson KJ, Axtell RA, Hoover SM, Kuhn SM, Pritchett J, Kehl SC, Klein JP: Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solutions: a randomized, multicenter, double-blind trial. J Clin Oncol 2000, 18:1269-1278.
45. Centers for Disease Control and Prevention: Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995, 44 (RR-12):1-13.
46. Raad I, Buzaid A, Rhyne J, Hachem R, Darouiche R, Safar H, Albitar M, Sherertz RJ: Minocycline and etylenediaminetetraacetate for the prevention of recurrent vascular catheter infections. Clin Infect Dis 1997, 25:149-151.
47. Chatzinikolaou I, Zipf TF, Hanna H, Umphrey J, Roberts WM, Sherertz R, Hachem R, Raad I: Minocycline-ethylenediamine tetracetate lock solution for the prevention of implantable port infections in children with cancer. Clin Infect Dis 2003, 36: 116-119.
48. Raad II, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP: The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994, 271:1014-1016.
49. Timsit JF, Farkas JC, Boyer JM, Martin JB, Misset B, Renaud B, Carlet J: Central vein catheter-related thrombosis in intensive care patients: incidence, risk factors, and relationship with catheter-related sepsis. Chest 1998, 113:165-171.
50. Pierce CM, Wade A, Mok Q: Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med 2000, 26:967-972.
51. Randolph AG, Cook DJ, Gonzales CA, Andrew M: Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomised controlled trials. Chest 1998, 113:165-171.
52. Donelli G, Francolini I, Piozzi A, Di Rosa R, Marconi W: New polymer-antibiotic systems to inhibit bacterial biofilm formation: a suitable approach to prevent central venous catheter-associated infections. J Chemother 2002, 14:501-507.
53. Schmidt S, Haase G, Csomor E, Lutticken R, Peltroche-Llacsahuanga H: Inhibitor of complement, Compstatin, prevents polymer-mediated Mac-1 up-regulation of human neutrophils independent of biomaterial type tested. J Biomed Mater Res 2003, 66A:491-499.
54. Parsek MR, Val DL, Hanzelka BL, Cronan JE Jr, Greenberg EP: Acyl homoserine-lactone quorum-sensing signal generation. Proc Natl Acad Sci USA 1999, 96:4360-4365.
55. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP: The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998, 280:295-298.